On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 22, 2022, Merck announced that that the U.S. Food and Drug Administration (FDA) had approved an…
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…
On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax…
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
On May 25, 2022, Pfizer and BioNTech announced topline safety, immunogenicity and vaccine efficacy data from a Phase…
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency to expand…
On May 19, 2022, WHO issued an emergency use listing (EUL) for CONVIDECIA, a vaccine manufactured by CanSino…
On May 18, 2022, Moderna and IAVI announced that the first participant screenings are soon to start for…
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwanï¾’s Food…
On May 12, 2022, WHOï¾’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement…
On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research…
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
On May 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had launched…
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
On Apr. 20, 2022, Codiak BioSciences announced new preclinical data from its pan beta-coronavirus vaccine program, which aims…
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…